# Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

> **NCT01238861** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 964 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** Benralizumab 2 mg
- **BIOLOGICAL:** Benralizumab 20 mg
- **BIOLOGICAL:** Benralizumab 100 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01238861
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2013-03
- **Final completion:** 2013-08
- **Target enrollment:** 964 (ACTUAL)
- **Last updated:** 2016-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01238861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01238861, "Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01238861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*